Selected research
Industry Research
Axillary Hyperhidrosis Drug Industry Research Report 2026
Market perspective
The global Axillary Hyperhidrosis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Axillary Hyperhidrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Axillary Hyperhidrosis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Axillary Hyperhidrosis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Axillary Hyperhidrosis Drug include GlaxoSmithKline Plc, TheraVida Inc, Dr. August Wolff GmbH & Co KG Arzneimittle, Dermira Inc, Brickell Biotech Inc and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Axillary Hyperhidrosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Axillary Hyperhidrosis Drug Market by Company
GlaxoSmithKline Plc
TheraVida Inc
Dr. August Wolff GmbH & Co KG Arzneimittle
Dermira Inc
Brickell Biotech Inc
Allergan Plc
Axillary Hyperhidrosis Drug Segment by Type
Botulinum ToxinA
Glycopyrronium Tosylate
Glycopyrrolate
Others
Axillary Hyperhidrosis Drug Segment by Application
Home Care
Hospital
Clinic
Axillary Hyperhidrosis Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axillary Hyperhidrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Axillary Hyperhidrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axillary Hyperhidrosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Axillary Hyperhidrosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Axillary Hyperhidrosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Axillary Hyperhidrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Botulinum ToxinA
- Glycopyrronium Tosylate
- Glycopyrrolate
- Others
Applications
- Home Care
- Hospital
- Clinic
Companies covered
- GlaxoSmithKline Plc
- TheraVida Inc
- Dr. August Wolff GmbH & Co KG Arzneimittle
- Dermira Inc
- Brickell Biotech Inc
- Allergan Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Axillary Hyperhidrosis Drug Market Size (2021-2032)
- 2.2.2 Global Axillary Hyperhidrosis Drug Sales (2021-2032)
- 2.2.3 Global Axillary Hyperhidrosis Drug Market Average Price (2021-2032)
- 2.3 Axillary Hyperhidrosis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Botulinum ToxinA
- 2.3.3 Glycopyrronium Tosylate
- 2.3.4 Glycopyrrolate
- 2.3.5 Others
- 2.4 Axillary Hyperhidrosis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Home Care
- 2.4.3 Hospital
- 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Axillary Hyperhidrosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Axillary Hyperhidrosis Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Axillary Hyperhidrosis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Axillary Hyperhidrosis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Axillary Hyperhidrosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Axillary Hyperhidrosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Axillary Hyperhidrosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Axillary Hyperhidrosis Drug, Established Date
- 3.9 Global Axillary Hyperhidrosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GlaxoSmithKline Plc
- 4.1.1 GlaxoSmithKline Plc Company Information
- 4.1.2 GlaxoSmithKline Plc Business Overview
- 4.1.3 GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Product Portfolio
- 4.1.5 GlaxoSmithKline Plc Recent Developments
- 4.2 TheraVida Inc
- 4.2.1 TheraVida Inc Company Information
- 4.2.2 TheraVida Inc Business Overview
- 4.2.3 TheraVida Inc Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 TheraVida Inc Axillary Hyperhidrosis Drug Product Portfolio
- 4.2.5 TheraVida Inc Recent Developments
- 4.3 Dr. August Wolff GmbH & Co KG Arzneimittle
- 4.3.1 Dr. August Wolff GmbH & Co KG Arzneimittle Company Information
- 4.3.2 Dr. August Wolff GmbH & Co KG Arzneimittle Business Overview
- 4.3.3 Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Product Portfolio
- 4.3.5 Dr. August Wolff GmbH & Co KG Arzneimittle Recent Developments
- 4.4 Dermira Inc
- 4.4.1 Dermira Inc Company Information
- 4.4.2 Dermira Inc Business Overview
- 4.4.3 Dermira Inc Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dermira Inc Axillary Hyperhidrosis Drug Product Portfolio
- 4.4.5 Dermira Inc Recent Developments
- 4.5 Brickell Biotech Inc
- 4.5.1 Brickell Biotech Inc Company Information
- 4.5.2 Brickell Biotech Inc Business Overview
- 4.5.3 Brickell Biotech Inc Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Brickell Biotech Inc Axillary Hyperhidrosis Drug Product Portfolio
- 4.5.5 Brickell Biotech Inc Recent Developments
- 4.6 Allergan Plc
- 4.6.1 Allergan Plc Company Information
- 4.6.2 Allergan Plc Business Overview
- 4.6.3 Allergan Plc Axillary Hyperhidrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Allergan Plc Axillary Hyperhidrosis Drug Product Portfolio
- 4.6.5 Allergan Plc Recent Developments
5 Global Axillary Hyperhidrosis Drug Market Scenario by Region
- 5.1 Global Axillary Hyperhidrosis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Axillary Hyperhidrosis Drug Sales by Region: 2021-2032
- 5.2.1 Global Axillary Hyperhidrosis Drug Sales by Region: 2021-2026
- 5.2.2 Global Axillary Hyperhidrosis Drug Sales by Region: 2027-2032
- 5.3 Global Axillary Hyperhidrosis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Axillary Hyperhidrosis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Axillary Hyperhidrosis Drug Revenue by Region: 2027-2032
- 5.4 North America Axillary Hyperhidrosis Drug Market Facts & Figures by Country
- 5.4.1 North America Axillary Hyperhidrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
- 5.4.3 North America Axillary Hyperhidrosis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Axillary Hyperhidrosis Drug Market Facts & Figures by Country
- 5.5.1 Europe Axillary Hyperhidrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Axillary Hyperhidrosis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Axillary Hyperhidrosis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Axillary Hyperhidrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Axillary Hyperhidrosis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Axillary Hyperhidrosis Drug Market Facts & Figures by Country
- 5.7.1 South America Axillary Hyperhidrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
- 5.7.3 South America Axillary Hyperhidrosis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Axillary Hyperhidrosis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Axillary Hyperhidrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Axillary Hyperhidrosis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Axillary Hyperhidrosis Drug Sales by Type (2021-2032)
- 6.1.1 Global Axillary Hyperhidrosis Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Axillary Hyperhidrosis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Axillary Hyperhidrosis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Axillary Hyperhidrosis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Axillary Hyperhidrosis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Axillary Hyperhidrosis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Axillary Hyperhidrosis Drug Sales by Application (2021-2032)
- 7.1.1 Global Axillary Hyperhidrosis Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Axillary Hyperhidrosis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Axillary Hyperhidrosis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Axillary Hyperhidrosis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Axillary Hyperhidrosis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Axillary Hyperhidrosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Axillary Hyperhidrosis Drug Value Chain Analysis
- 8.1.1 Axillary Hyperhidrosis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Axillary Hyperhidrosis Drug Production Mode & Process
- 8.2 Axillary Hyperhidrosis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Axillary Hyperhidrosis Drug Distributors
- 8.2.3 Axillary Hyperhidrosis Drug Customers
9 Global Axillary Hyperhidrosis Drug Analyzing Market Dynamics
- 9.1 Axillary Hyperhidrosis Drug Industry Trends
- 9.2 Axillary Hyperhidrosis Drug Industry Drivers
- 9.3 Axillary Hyperhidrosis Drug Industry Opportunities and Challenges
- 9.4 Axillary Hyperhidrosis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst